Association of the IL-1B rs1143623 Polymorphism and Cancer Risk: A Meta-Analysis

To derive a more precise association between the interleukin-1 beta (IL-1B) gene polymorphism rs1143623 and cancer risk. Published case-control studies up to November 5, 2019, that met all inclusion criteria were identified using PubMed, Web of Science, and EMBASE. Odds ratios and 95% confidence intervals were calculated to estimate the strength of associations using multiple genetic models. Sensitivity analyses and publication biases were also performed. Nine articles covering 11 case-control studies, with 4801 cases and 6116 controls, were included in this meta-analysis. No significant association between the IL-1B rs1143623 polymorphism and cancer risk was observed under the homozygous, heterozygous, dominant, recessive, or allelic genetic models (all p > 0.05). Subgroup analysis by ethnicity indicated that the IL-1B rs1143623 polymorphism may decrease the risk of cancer in Asians under the heterozygous and dominant genetic models (both p < 0.05). Sensitivity analyses showed that none of the individual studies significantly affected the overall results. No significant publication biases were detected in this meta-analysis. Our results suggest that there is no significant association between the IL-1B rs1143623 polymorphism and cancer risk in the overall human population, but that it may provide a protective affect among Asians.